We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 05, 2022

Pregnancy Outcomes After Early Fetal Exposure to Injectable First-Line Treatments, Dimethyl Fumarate, or Natalizumab in Danish Women With MS

European Journal of Neurology


Additional Info

Disclosure statements are available on the authors' profiles:

European Journal of Neurology
Pregnancy outcomes after early fetal exposure to injectable first-line treatments, dimethyl fumarate or natalizumab in Danish women with multiple sclerosis
Eur. J. Neurol. 2022 Sep 13;[EPub Ahead of Print], JB Andersen, F Sellebjerg, M Magyari

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading